metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
endometrial cancer endometrial cancer
versus placebo plus SoC
	atezolizumab plus SoC
	AtTEnd, 2023 Ann Onc. 2023;34(S2):S1277 NCT03603184	RCT	endometrial cancer	atezolizumab	placebo	Women With Advanced/Recurrent Endometrial Cancer	360 / 189	NA	suggested	suggested 26 % decrease in progression or deaths (PFS) Interim analysis of OS in all comers indicated a trend in favor for atezo, despite 45 (24.3%) placebo patients received immunotherapy as subsequent therapy. Second PFS and duration of response in the dMMR population confirmed the efficacy of atezo
	dostarlimab plus soC
	RUBY (part 1), 2023 NCT03981796	RCT	endometrial cancer	dostarlimab (500 mg)	placebo	primary advanced stage III or IV or first recurrent endometrial cancer	245 / 249	low	conclusif	demonstrated 31 % decrease in deaths (OS) (PE) suggested 36 % decrease in progression or deaths (PFS) (PE)
	durvalumab plus olaparib plus SoC
	DUO-E (durvalumab follow by durvalumab and olaparib vs control arms) DUPLICATE, 2023 NCT04269200	RCT	endometrial cancer	durvalumab	placebo	Patients With Newly Diagnosed Advanced or Recurrent Endometrial Cancer	241 / 239	low	conclusif	suggested 41 % decrease in deaths (OS) demonstrated 45 % decrease in progression or deaths (PFS) (PE)
	durvalumab plus SoC
	DUO-E (durvalumab then durvalumab alone vs control arms), 2023 NCT04269200	RCT	endometrial cancer	durvalumab	placebo	Patients With Newly Diagnosed Advanced or Recurrent Endometrial Cancer	238 / 239	low	conclusif	demonstrated 29 % decrease in progression or deaths (PFS) (PE)
	dostarlimab plus soC, niraparib
	RUBY (part 2), 2024 NCT03981796	RCT	endometrial cancer	dostarlimab (500 mg) followed by dostarlimab plus niraparib	placebo	primary advanced stage III or IV or first recurrent endometrial cancer	-/-	low	suggested	suggested 40 % decrease in progression or deaths (PFS),progression or deaths (PFS) (PE) The PFS improvement with dostarlimab was observed in the overall patient population and in a subset of patients with mismatch repair–proficient (MMRp) or microsatellite stable (MSS) tumors, meeting the primary end point of the study. Data pertaining to overall survival (OS), a key secondary end point, are immature but will continue to be followed.
	pembrolizumab plus SoC
	NRG-GY018_dMMR, 2023 NCT03914612	RCT	endometrial cancer	pembrolizumab	placebo	Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer. The patients were stratified into two cohorts according to whether they had mismatch repair–deficient (dMMR) or mismatch repair–proficient (pMMR) disease	112 / 113	low	conclusif	demonstrated 70 % decrease in progression or deaths (PFS) (PE) press realease 03/2024 : OS 0.55 [0.25; 1.19] not indexed in the results due to lack of information on the timepoint for this analysis
	NRG-GY018_pMMR, 2023 NCT03914612	RCT	endometrial cancer	pembrolizumab	placebo	Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer. The patients were stratified into two cohorts according to whether they had mismatch repair–deficient (dMMR) or mismatch repair–proficient (pMMR) disease	295 / 296	low	conclusif	demonstrated 46 % decrease in progression or deaths (PFS) (PE) press realease 03/2024 : OS 0.79 [0.53; 1.17]not indexed in the results due to lack of information on the timepoint for this analysis
versus Standard of Care (SoC)
	avelumab plus SoC
	MITO END-3, 2023 Lancet Oncol 2023; 24:286-296-. NCT03503786	RCT	endometrial cancer	avelumab SoC	Standard of care	histologically confirmed advanced (FIGO stage III–IV) or recurrent endometrial cancer, an Eastern Cooperative Oncology Group (ECOG) performance status of 0–1, and no previous systemic anticancer therapy as primary treatment for advanced or metastatic disease	63 / 62	some concern	inconclusive	no statistically significant result
	pembrolizumab plus lenvatinib
	LEAP-001/ENGOT-en9, 2024 NCT03884101	RCT	endometrial cancer	pembrolizumab plus levitinib	carboplatine plus paclitaxel	First-line Treatment of Advanced or Recurrent Endometrial Carcinoma	-/-	NA	inconclusive	inconclusive 7 % decrease in deaths (OS) (PE) inconclusive 9 % decrease in progression or deaths (PFS) (PE)
	lenvatinib in association, pembrolizumab plus lenvatinib
	KEYNOTE-775, 2023 New England Journal of Medicine NCT03517449	RCT	endometrial cancer	pembrolizumab plus lenvatinib	Paclitaxel or Doxorubicin	Participants With Advanced recurrent or metastatic Endometrial Cancer. Eligible women had disease progression after the receipt of one previous platinum-based chemotherapy regimen	411 / 416	some concern	conclusif	suggested 35 % decrease in deaths (OS),deaths (OS) (PE) demonstrated 44 % decrease in progression or deaths (PFS),progression or deaths (PFS) (PE) suggested 44 % decrease in PFS (extension),PFS (extension)

endometrial cancer endometrial cancer